AlphaCentric Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

AlphaCentric Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$382K	Sell	20,000 -10,500	-34%	-$231K	0.11%	73
2021 Q3	$752K	Sell	30,500 -3,000	-9%	-$70.7K	0.19%	48
2021 Q2	$872K	Buy	33,500 +30,500	+1,017%	+$793K	0.24%	31
2021 Q1	$95K	Buy	3,000 +1,000	+50%	+$41.5K	0.03%	159
2020 Q4	$93K	Buy	2,000 +850	+74%	+$33.7K	0.04%	145
2020 Q3	$38K	Hold	1,150	–	–	0.02%	123
2020 Q2	$32K	Buy	+1,150	New	+$37.8K	0.02%	104

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlphaCentric Advisors's IOVA Position: Q4 2021 in Review

AlphaCentric Advisors reduced its Iovance Biotherapeutics (IOVA) stake by 34% in Q4 2021, selling an estimated $231K and leaving 20,000 shares worth $382K. The position accounts for 0.11% of the portfolio, ranked #73.

AlphaCentric Advisors first reported a position in IOVA in Q2 2020 and has held it in 7 quarters since. The position peaked at $872K in Q2 2021. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

AlphaCentric Advisors held 20,000 shares of Iovance Biotherapeutics worth $382K as of Q4 2021.
AlphaCentric Advisors sold 10,500 Iovance Biotherapeutics shares in Q4 2021, an estimated $231K.
Iovance Biotherapeutics made up 0.11% of AlphaCentric Advisors's portfolio in Q4 2021, its #73 holding.
AlphaCentric Advisors first reported a position in Iovance Biotherapeutics in Q2 2020 and has held it in 7 quarters since.
AlphaCentric Advisors's Iovance Biotherapeutics position peaked at $872K in Q2 2021.
246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.